You are here: Industry Insights > B.1.351

News List

Scientists identify drug that prevents multiple coronavirus variants expresspharma
June 01, 2021
Scientists have identified a new drug which is highly effective in preventing severe COVID-19 in mice infected with SARS-CoV-2, and could also treat other respiratory coronaviruses.
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate worldpharmanews
May 28, 2021
Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
Novavax Covid-19 vaccine provides cross-protection against B.1.351 variant pharmaceutical-technology
May 07, 2021
The protein-based vaccine candidate NVX-CoV2373 is made from the genetic sequence of the first SARS-CoV-2 strain. It is adjuvanted with the company’s saponin-based Matrix-M to boost immune response and neutralising antibodies.
Monoclonal antibodies against COVID-19 have high potential, but efficacy against emerging variants muddled: GlobalData expresspharma
April 23, 2021
The prevalence of more transmissible strains is growing fast and may require adjustments to current therapies to ensure they retain clinical efficacy.
First patients receive Moderna’s modified COVID-19 vaccine candidates europeanpharmaceuticalreview
March 12, 2021
Moderna has begun testing two new mRNA COVID-19 vaccines, one specifically targeting the B.1.351 variant and the other a multivalent candidate.
COVID-19 booster shots more likely as variants could cut efficacy of vaccines: GlobalData expresspharma
March 10, 2021
Pfizer and Moderna are already working on developing booster shots for their vaccines to improve their effectiveness against the B.1.351 strain.
Experiment showed that Jemincare's neutralizing antibody JMB2002 would likely keep the potency against the South African mutant prnasia
February 09, 2021
On February 7, 2021, scientists from Jemincare Shanghai Research Institute published a preprint paper on BioRxiv, the paper entitled "A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed ...
Study finds some antibody therapies are not effective against new COVID-19 variants europeanpharmaceuticalreview
January 29, 2021
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against the new SARS-CoV-2 variants, while other antibody therapies, including Eli Lilly’s bamlanivimab, were not.